Other substances

Terlipressin

A polypeptide vasopressin derivative.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Terlipressin on PubChem

Marketed as

GLYPRESSIN; LUCASSIN; TERIPRESS

 

Structure image - Terlipressin

C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N

Supporting references

Link Tested on Impact factor Notes Publication date
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
Spike protein 3CLpro In silico 		in silico 4.07

Predicted to bind the SARS-CoV-2 spike protein.

 Sep/07/2020

AI-suggested references

Link Publication date
Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings
May/13/2021
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Nov/20/2021
Export (.csv)